Botanix Pharmaceuticals Limited (ASX:BOT)

Australia flag Australia · Delayed Price · Currency is AUD
0.0350
-0.0020 (-5.41%)
Apr 20, 2026, 3:59 PM AEST
Market Cap92.29M -88.6%
Revenue (ttm)21.92M +959.2%
Net Income-88.70M
EPS-0.05
Shares Out2.64B
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume18,098,120
Average Volume28,454,613
Open0.0360
Previous Close0.0370
Day's Range0.0350 - 0.0360
52-Week Range0.0340 - 0.4750
Beta1.01
RSI31.38
Earnings DateMay 28, 2026

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited operates as a commercial dermatology company in Australia and the United States. The company’s lead product is Sofdra (sofpironium) topical gel, a prescription anticholinergic medicine used on the skin to treat underarm sweating in adults and children 9 years of age and older. Its product pipeline includes BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers; BTX 1801 for treating staphylococcus aureus and methicillin resistant staphylococcus aureus; BTX 1702 for the t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1984
Employees 11
Stock Exchange Australian Securities Exchange
Ticker Symbol BOT
Full Company Profile

Financial Performance

In fiscal year 2025, Botanix Pharmaceuticals's revenue was 5.79 million, an increase of 179.74% compared to the previous year's 2.07 million. Losses were -86.40 million, 522.9% more than in 2024.

Financial Statements